Physician profile
John M Rutkowski
NPI 1902061914
$6,294.45
in general payments reported to CMS, 2019-2025
30 companies · $989 in 2025
The $989 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,724 · 2020: $94.31 · 2021: $1,097 · 2022: $163 · 2023: $638 · 2024: $1,589 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Consulting Fee: $818 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.19 |
| Consulting Fee | $817.50 |
| Education | $177.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,236.61 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $817.50 | 2024 | Erleada |
| Astellas Pharma US INC | $814.95 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $356.48 | 2022-2025 | Erleada, Carvykti, Rybrevant |
| Sumitomo Pharma America, INC. | $329.18 | 2023-2025 | Orgovyx, Gemtesa |
| Medtronic, INC. | $232.83 | 2023-2024 | Ligasure, Interstim, Signia |
| Abbvie INC. | $189.25 | 2021-2023 | Lupron Depot, Botox |
| Bayer Healthcare Pharmaceuticals INC. | $163.49 | 2024-2025 | |
| Boston Scientific Corporation | $148.78 | 2025 | General - Erectile Dysfunction |
| Pfizer INC. | $139.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $121.71 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Endogastric Solutions, INC | $120.20 | 2024 | Esophyx |
| Ferring Pharmaceuticals INC. | $107.96 | 2019-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $82.67 | 2022-2025 | Myrisk, Prolaris |
| Olympus America INC. | $58.32 | 2023-2024 | Itind System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $53.42 | 2020-2021 | |
| Urogen Pharma, INC. | $50.97 | 2024 | |
| Allergan, INC. | $48.92 | 2019-2021 | |
| Urovant Sciences INC | $38.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $38.02 | 2022-2023 | |
| Acera Surgical, INC. | $29.61 | 2025 | Restrata Wound Matrix |
| Calyxo, INC. | $25.37 | 2025 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $23.38 | 2019 | |
| Axonics, INC. | $19.21 | 2021 | |
| 180 Medical, INC. | $18.44 | 2021 | |
| Covidien LP | $11.97 | 2019 | |
| Ethicon US, LLC | $11.75 | 2021 | |
| Ambu INC. | $5.82 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rutkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.